Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial.
To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 x 10(6) to 109 x 10(6)24 h (P < .02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10(6)/24 h for the 6 initially treated with drug (P < .02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P < .05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.
White
A C
AC
Dept. of Medicine, Baylor College of Medicine, Houston, TX 77030.
Chappell
C L
CL
Hayat
C S
CS
Kimball
K T
KT
Flanigan
T P
TP
Goodgame
R W
RW
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D003457:Cryptosporidiosis / Q000188:drug therapy*; D003967:Diarrhea / Q000188:drug therapy; D004311:Double-Blind Method; D005243:Feces / Q000469:parasitology; D006801:Humans; D008137:Longitudinal Studies; D010270:Parasite Egg Count; D010303:Paromomycin / Q000627:therapeutic use*; D011446:Prospective Studies
D010303:Paromomycin